PBAC Public Summary Document - April 2013
Public Summary Documents relating to the April 2013 PBAC meeting.
- Everolimus, tablets, 2.5 mg, 5 mg and 10 mg, Afinitor®
- Linagliptin with metformin hydrochloride, tablets, 2.5 mg/500 mg, 2.5 mg/850 mg and 2.5 mg/1000 mg, Trajentamet®
- Rifaximin, tablet, 550 mg, Xifaxan®
- Saxagliptin with Metformin, tablet, 2.5 mg/500 mg, 2.5 mg/850 mg and 2.5 mg/1000 mg, Kombiglyze®
